Affinage

RCC2

Protein RCC2 · UniProt Q9P258

Length
522 aa
Mass
56.1 kDa
Annotated
2026-06-10
38 papers in source corpus 23 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 9/9 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

RCC2 (TD-60) is an RCC1-family protein that operates both as a mitotic chromosome passenger protein and as a guanine nucleotide exchange factor that gates small-GTPase signaling during cell division and migration (PMID:12919680, PMID:26158537). In mitosis it colocalizes with INCENP at centromeres and the spindle midzone (PMID:9914378) and is required for spindle assembly: its depletion arrests cells in prometaphase, triggers the spindle assembly checkpoint, and abolishes centromeric recruitment of the chromosome passenger complex (survivin, Aurora B) (PMID:12919680). RCC2 acts as a direct cofactor for Aurora-B activation in vitro and localizes both the CPC and Haspin kinase activity to centromeres (PMID:18218899). A central biochemical activity is GEF activity toward RalA, which lies downstream of RCC2 in CPC regulation, since GTP-locked RalA reverts the mitotic phenotypes of RCC2 depletion (PMID:26158537). RCC2 also engages Rac1 through a unique β-hairpin in its RCC1-like domain resolved by crystallography, binding the nucleotide-free form and the GTPase switch regions to competitively block GEF access; this restrains Rac1 to polarize protrusions during mesenchymal migration, acting within a trimeric complex with coronin-1C and downstream of a p53/RCC2/Rac1 axis (PMID:12919680, PMID:25074804, PMID:28869598). RCC2 is essential for interphase cell cycle progression, with depletion blocking the G1/S and G2/M transitions (PMID:23388455). During cytokinesis RCC2 is stabilized at the midbody by the NudCL2/Hsp90 chaperone complex, and its loss causes cytokinesis failure and multinucleation (PMID:38801297). RCC2 is controlled post-translationally by KAT2A-mediated K124 lactylation that promotes SERBP1 recruitment and MAD2L1 mRNA stabilization (PMID:40145796), and by Aurora A-dependent Thr418 phosphorylation that triggers K377 ubiquitination and degradation (PMID:39908861, PMID:41090358); its transcription is governed by p53 and a BRD4–TP73 complex (PMID:28869598, PMID:34750516). Across cancers RCC2 acts as an oncogenic effector signaling through RalA and Rac1 to influence proliferation, migration, invasion, EMT, and apoptosis (PMID:28606921, PMID:29321004, PMID:30768358).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1998 Medium

    Established that RCC2/TD-60 behaves as a chromosome passenger protein by tracking its dynamic localization through mitosis alongside a known passenger.

    Evidence Confocal immunofluorescence colocalization with INCENP through G2 and mitosis in cultured cells

    PMID:9914378

    Open questions at the time
    • Colocalization only; no biochemical interaction with INCENP demonstrated
    • Functional role in cytokinesis inferred, not tested by perturbation
  2. 2003 High

    Identified RCC2 as an RCC1-family protein that binds nucleotide-free Rac1 and is functionally required for spindle assembly and CPC recruitment, defining its core mitotic role.

    Evidence Protein purification/cloning, co-precipitation with nucleotide-free Rac1, and siRNA knockdown with cell-cycle and immunofluorescence readouts

    PMID:12919680

    Open questions at the time
    • Did not establish whether Rac1 binding is mechanistically required for the mitotic phenotype
    • GEF activity not yet demonstrated
  3. 2008 High

    Demonstrated that RCC2 is a direct cofactor for Aurora-B kinase activation and is required to localize the CPC and Haspin to centromeres, placing it upstream in centromeric signaling.

    Evidence In vitro Aurora-B activation reconstitution plus siRNA and immunofluorescence localization

    PMID:18218899

    Open questions at the time
    • Molecular mechanism by which RCC2 activates Aurora-B not resolved
    • Link between RCC2 GTPase activity and Aurora-B activation undefined at this stage
  4. 2013 Medium

    Extended RCC2 function beyond mitosis by showing it is required for interphase cell cycle transitions and associates with Rac1 and Arf6.

    Evidence siRNA knockdown with flow-cytometry cell cycle analysis and co-IP in transformed and non-transformed cells

    PMID:23388455

    Open questions at the time
    • Arf6 functional relationship not mechanistically dissected
    • Whether interphase defects are GEF-dependent unknown
  5. 2014 High

    Defined how RCC2 controls cell migration by binding Rac1 switch regions to block GEF action and partnering with coronin-1C, providing an in vivo migration phenotype.

    Evidence Reciprocal co-IP defining an RCC2–Coro1C–Rac1 complex, migration assays, and zebrafish morpholino knockdown

    PMID:25074804

    Open questions at the time
    • Identity of the GEFs being competed not defined
    • Coro1C-mediated Rac1 redistribution mechanism partly inferential
  6. 2015 High

    Resolved the enzymatic identity of RCC2 as a RalA GEF and placed RalA downstream of RCC2 in CPC regulation via epistasis.

    Evidence In vitro GEF assay, siRNA, and rescue with GTP-locked RalA(Q72L)

    PMID:26158537

    Open questions at the time
    • How RalA-GTP feeds into CPC regulation mechanistically not defined
    • Relationship between RalA-GEF and Rac1-binding activities of the same protein unresolved
  7. 2017 High

    Integrated transcriptional and structural control by showing p53 transcriptionally regulates RCC2 and that a β-hairpin in the RCC1-like domain mediates Rac1 binding to direct migration.

    Evidence ChIP, crystal structure with site-directed mutagenesis, co-IP, and haptotaxis rescue in p53-null cells

    PMID:28869598

    Open questions at the time
    • Structural basis of RalA GEF activity not captured
    • How p53 loss couples to Rac1 hyperactivation beyond RCC2 levels not fully resolved
  8. 2017 Medium

    Linked RCC2 to oncogenic migration/invasion through JNK signaling in lung adenocarcinoma.

    Evidence Overexpression/knockdown, mouse model, and pharmacological JNK inhibition with EMT/MMP readouts

    PMID:28606921

    Open questions at the time
    • Direct molecular connection between RCC2 and JNK activation not shown
    • GTPase dependence of the JNK effect untested
  9. 2018 Medium

    Showed RCC2 suppresses apoptosis specifically through Rac1 inhibition using GTPase epistasis.

    Evidence Overexpression/knockdown apoptosis assays with constitutively active Rac1(Q61L) rescue

    PMID:29321004

    Open questions at the time
    • Downstream apoptotic effectors of Rac1 not defined
    • Single cell-line context
  10. 2019 Medium

    Established RCC2–RalA signaling as oncogenic in gastric cancer, with RalA downstream of RCC2 in proliferation, apoptosis, and migration.

    Evidence Co-IP, GTP-RalA pulldown, RBC8 inhibitor, and reciprocal RalA epistasis rescue

    PMID:30768358 PMID:32341655

    Open questions at the time
    • RalBP1/MAPK-JNK branch only partly mapped
    • Single tumor type
  11. 2022 Medium

    Identified additional mitotic and cancer-relevant physical partners of RCC2 (cortactin, HMGA2) and a glioma G2/M and metabolic axis.

    Evidence SILAC-MS and reciprocal co-IP (cortactin); co-IP (HMGA2); gene silencing with RNA-seq, metabolomics, and BACH1 stabilization assays (glioma)

    PMID:22282019 PMID:36116740 PMID:36340602

    Open questions at the time
    • Functional consequence of the cortactin interaction not established
    • HMGA2 interaction lacks rescue linking it to a mechanism
    • BACH1 stabilization mechanism not structurally defined
  12. 2022 Medium

    Revealed post-transcriptional control of RCC2 abundance via m6A reader IGF2BP3 in leukemia.

    Evidence RNA immunoprecipitation, IGF2BP3 knockdown with RCC2 Western blot, and leukemia assays

    PMID:35217832

    Open questions at the time
    • m6A sites on RCC2 mRNA not mapped
    • Generalizability beyond AML untested
  13. 2024 High

    Defined chaperone-mediated stabilization of RCC2 at the midbody, placing RCC2 downstream of NudCL2/Hsp90 in cytokinesis.

    Evidence NudCL2 knockout, iTRAQ proteomics, co-IP, and ectopic RCC2 rescue of cytokinesis defects

    PMID:38801297

    Open questions at the time
    • Whether Hsp90 binds RCC2 directly or via NudCL2 not fully resolved
    • How midbody stabilization couples to RCC2 GEF activity unknown
  14. 2025 Medium

    Established two opposing layers of post-translational control: activating K124 lactylation (KAT2A/SERBP1/MAD2L1) and degradative Thr418 phosphorylation-driven K377 ubiquitination.

    Evidence PTM site mapping, KAT2A/SERBP1 co-IP and mRNA stability assays; Aurora A and CD24-driven ubiquitination with Thr418/K377 mutagenesis and metastasis assays

    PMID:39908861 PMID:40145796 PMID:41090358

    Open questions at the time
    • E3 ligase mediating K377 ubiquitination not identified
    • Crosstalk between lactylation and ubiquitination not tested
    • Vimentin-degradation arm needs mechanistic depth

Open questions

Synthesis pass · forward-looking unresolved questions
  • How RCC2's dual GTPase-regulatory activities (RalA GEF vs Rac1 GEF inhibition) are coordinated within single cells and tied to its mitotic versus migratory functions remains unresolved.
  • No structure capturing simultaneous RalA and Rac1 engagement
  • Mechanism switching RCC2 between mitotic CPC role and interphase migration role unknown
  • Whether PTMs (lactylation, phosphorylation) toggle GTPase-target selectivity untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 4 GO:0008092 cytoskeletal protein binding 2 GO:0140096 catalytic activity, acting on a protein 1
Localization
GO:0005694 chromosome 2 GO:0005886 plasma membrane 1
Pathway
R-HSA-1640170 Cell Cycle 5 R-HSA-162582 Signal Transduction 4 R-HSA-1266738 Developmental Biology 1
Partners
ARF6CORO1CCTTNINCENPNUDCD3RAC1RALASERBP1
Complex memberships
NudCL2/Hsp90 chaperone complex (client)RCC2–Coronin-1C–Rac1 complexchromosome passenger complex (CPC) regulator

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 TD-60 (RCC2) was purified and cloned as a member of the RCC1 family; it binds preferentially to the nucleotide-free form of small GTPase Rac1. siRNA depletion of TD-60 suppresses overall spindle assembly, blocks cells in prometaphase, activates the spindle assembly checkpoint, and prevents recruitment of passenger proteins survivin and Aurora B to centromeres. Protein purification, cloning, co-precipitation with nucleotide-free Rac1, siRNA knockdown with immunofluorescence and cell cycle analysis Developmental cell High 12919680
1998 TD-60 (RCC2) and INCENP colocalize identically throughout G2 and mitosis, both concentrating at centromeres in prophase and redistributing to the spindle midzone and cortex during anaphase/cytokinesis, suggesting they cooperate in signaling cytokinesis as chromosome passenger proteins. Confocal immunofluorescence microscopy, pixel count colocalization analysis, dihydrocytochalasin B treatment Chromosoma Medium 9914378
2008 Aurora-B activation in vitro requires two cofactors: TD-60 (RCC2) and microtubules. TD-60 is critical for localizing both the chromosome passenger complex (CPC) and Haspin kinase activity to centromeres. Additionally, Aurora-B substrate phosphorylation by centromeric kinases Plk1 and Haspin relieves substrate-mediated inhibition of Aurora-B activation. In vitro Aurora-B kinase activation assay, siRNA depletion, immunofluorescence localization of CPC components and Haspin Science (New York, N.Y.) High 18218899
2013 TD-60 (RCC2) is an essential regulator of interphase cell cycle progression; siRNA suppression blocks G1/S phase progression and G2-to-mitosis transition in both non-transformed and p53-null cells. TD-60 associates with Rac1 and Arf6 in interphase. siRNA knockdown, cell cycle analysis (flow cytometry), co-immunoprecipitation with Rac1 and Arf6 Cell cycle (Georgetown, Tex.) Medium 23388455
2014 RCC2 guides mesenchymal migration by binding to the switch regions of Rac1 and competitively inhibiting GEF action, thereby preventing off-axial protrusion. RCC2 interacts with coronin-1C (Coro1C) and Rac1 in a trimeric complex; Coro1C mediates release of inactive Rac1 from non-protrusive membranes for redistribution to the leading edge. Morpholino knockdown of RCC2 in zebrafish delays arrival of neural crest derivatives at correct locations in vivo. RNA interference, Co-immunoprecipitation, 1D/3D migration assays, zebrafish morpholino knockdown Journal of cell science High 25074804
2015 TD-60/RCC2 exhibits guanine exchange factor (GEF) activity for the small GTPase RalA, both in vitro and in cells. TD-60 or RalA depletion causes spindle abnormalities and abnormal centromeric accumulation of CPC components in prometaphase. Expression of GTP-locked RalA(Q72L) reverts several mitotic phenotypes caused by TD-60 depletion, placing RalA downstream of TD-60 in CPC regulation. In vitro GEF activity assay, siRNA depletion, epistasis rescue with GTP-locked RalA mutant, immunofluorescence Nature communications High 26158537
2017 p53 is a transcriptional regulator of RCC2, acting through a palindromic binding motif in the RCC2 promoter. RCC2 physically interacts with Rac1 via a unique β-hairpin in its RCC1-like domain (identified by crystal structure). p53 or RCC2 deficiency leads to Rac1 activation and impaired haptotaxis; ectopic RCC2 restores directional migration in p53-null cells, defining a p53/RCC2/Rac1 axis. Chromatin immunoprecipitation (ChIP), crystal structure determination, co-immunoprecipitation, site-directed mutagenesis of RCC2 β-hairpin, haptotaxis assay, overexpression rescue Oncogene High 28869598
2017 RCC2 overexpression in lung adenocarcinoma cells promotes cell migration, invasion, and EMT, and activates JNK signaling. JNK inhibition suppresses the RCC2-mediated effects on migration, invasion, EMT, and MMP-2/MMP-9 expression, placing RCC2 upstream of MAPK-JNK in this context. Forced overexpression, siRNA knockdown, in vivo mouse model, pharmacological JNK inhibition, Western blotting for EMT markers and MMPs Clinical cancer research Medium 28606921
2018 RCC2 regulates apoptosis by blocking Rac1 signaling; forced RCC2 expression blocks spontaneous or staurosporine-induced apoptosis, while RCC2 knockdown increases apoptosis. The protective activity of RCC2 is revoked by constitutively active Rac1(Q61L), confirming that RCC2 acts through Rac1 inhibition. Overexpression and siRNA knockdown in cancer cell lines, apoptosis assays, epistasis with constitutively active Rac1 mutant BMC cancer Medium 29321004
2019 RCC2 interacts with RalA and promotes downstream RalBP1 activity. RCC2 knockdown decreases RalA-GTP levels and increases MAPK/JNK phosphorylation in gastric cancer cells. RalA knockdown reverses the effects of RCC2 overexpression on cell proliferation, apoptosis, and migration, while RalA overexpression alleviates the effects of RCC2 knockdown, confirming RalA is downstream of RCC2 in these processes. Co-immunoprecipitation, GTP-RalA pulldown assay, siRNA knockdown, epistasis rescue with RalA overexpression/knockdown, RBC8 pharmacological inhibitor FASEB journal Medium 30768358
2019 RCC2 promotes glioblastoma proliferation and radioresistance via p-STAT3-dependent transcriptional activation of DNMT1. shRNA inhibition of RCC2 reduced tumor proliferation and tumorigenicity in vitro and in vivo, and pharmacological inhibition of DNMT1 attenuated tumor growth. shRNA knockdown, in vivo tumor models, DNMT1 inhibitor treatment, pathway analysis implicating JAK-STAT signaling Biochemical and biophysical research communications Low 31277942
2020 RCC2 upregulates and stabilizes Sox2 expression by inhibiting ubiquitination-mediated proteasome degradation, and increases Sox2 transcriptional activity and promoter binding. Conditional RCC2 knockout in mice reduces esophageal tumor formation and PCNA expression. Overexpression/knockdown, ubiquitination assay, Sox2 promoter-binding assay, conditional knockout mouse model, immunohistochemistry Molecular cancer research : MCR Medium 32801160
2020 RCC2 mediates cisplatin resistance and metastatic behavior in hepatocellular carcinoma via regulation of AKT and Bcl2 survival pathways; RCC2 silencing inhibits proliferation, migration, invasion, and increases apoptosis upon cisplatin treatment. Lentivirus-based shRNA, cell proliferation/migration/invasion assays, apoptosis assay, Western blotting for AKT and Bcl2 Human cell Low 32239438
2020 RCC2 interacts with RalA in gastric cancer cells; RCC2 knockdown decreases RalA-GTP and alters MAPK/JNK phosphorylation, while the effects are confirmed by use of RBC8 (a Ral GTPase inhibitor). RCC2 knockdown inhibits tumor progression in vivo. Co-immunoprecipitation, GTP-RalA pulldown, RBC8 inhibitor, in vivo tumor model, siRNA knockdown OncoTargets and therapy Medium 32341655
2021 BRD4 drives RCC2 transcription through a BRD4-TP73 complex that binds the RCC2 promoter. Inhibition of BRD4 (genetic or pharmacological) decreases RCC2 expression and ESCC cell proliferation in vitro and in PDX models. Proteomic/transcriptomic analysis, ChIP or promoter binding assay, BRD4 inhibitors, PDX tumor model Oncogene Medium 34750516
2022 The m6A reader IGF2BP3 interacts with RCC2 mRNA and stabilizes m6A-modified RCC2 RNA, thereby maintaining RCC2 protein expression in AML cells. IGF2BP3 knockdown reduces RCC2 levels and impairs leukemic cell survival. RNA immunoprecipitation (RIP), knockdown of IGF2BP3 with Western blot for RCC2, in vitro and in vivo leukemia assays Experimental & molecular medicine Medium 35217832
2022 RCC2 regulates G2/M progression via CDC2 phosphorylation at Tyrosine 15 in glioma cells. Additionally, RCC2 stabilizes the transcription factor BACH1 at its C-terminus, leading to transcriptional upregulation of hexokinase 2 (HK2) and promotion of glycolysis and pentose phosphate pathway activity, defining a PTEN/RCC2/BACH1/HK2 signaling axis. Gene silencing, RNA-sequencing, metabolomics, Western blotting for CDC2-pY15, co-immunoprecipitation/stabilization of BACH1 Cancer letters Medium 36116740
2012 RCC2/TD60 physically interacts with cortactin in mitotic cells, identified by SILAC-based mass spectrometry and confirmed by reciprocal co-immunoprecipitation. Both proteins colocalize in the equatorial plane of dividing HeLa cells. SILAC mass spectrometry pulldown, reciprocal co-immunoprecipitation, immunofluorescence colocalization Journal of proteomics Medium 22282019
2024 NudCL2, a co-chaperone of Hsp90, localizes to the midbody and stabilizes RCC2 protein at the midbody in a complex with Hsp90. NudCL2 knockout reduces RCC2 levels; Hsp90 inhibition destabilizes RCC2. RCC2 depletion mirrors NudCL2 KO phenotypes (cytokinesis failure, multinucleation, midbody disorganization). Ectopic RCC2 rescues cytokinesis defects in NudCL2-depleted cells, placing RCC2 downstream of NudCL2/Hsp90 in the cytokinesis pathway. NudCL2 knockout, iTRAQ-based quantitative proteomics, co-immunoprecipitation, rescue experiment with ectopic RCC2 expression, immunofluorescence Protein & cell High 38801297
2025 RCC2 undergoes lactylation at lysine K124, mediated by the acyltransferase KAT2A. This lactylation event assists RCC2 in recruiting free SERBP1, thereby stabilizing MAD2L1 mRNA and activating the MAD2L1 signaling pathway to promote breast cancer cell proliferation under high-glucose conditions. Post-translational modification mapping (K124 lactylation site), KAT2A identification as writer enzyme, co-immunoprecipitation with SERBP1, mRNA stability assay, small molecule inhibitor blocking RCC2 active pocket Advanced science (Weinheim, Baden-Wurttemberg, Germany) Medium 40145796
2025 ROS accumulation induced by GPx4 inhibition activates Aurora A phosphorylation, which leads to RCC2 ubiquitination and degradation; the Thr418 phosphorylation site on RCC2 is crucial for its ubiquitination at K377. CD24 also targets RCC2 for degradation. RCC2 controls cell migration by promoting ubiquitination and degradation of vimentin, affecting cytoskeletal dynamics. CD24 knockdown inhibits β-catenin signaling by preventing RCC2 degradation (which otherwise suppresses AXIN2 and APC). Proteomic analysis, site-directed mutagenesis (Thr418, K377), ubiquitination assay, co-immunoprecipitation, ROS quantification, in vitro and in vivo metastasis assays Redox biology / The Journal of clinical investigation Medium 39908861 41090358
2022 RCC2 binds to HMGA2 by co-immunoprecipitation in colorectal cancer cells, and ectopic RCC2 expression promotes proliferation, migration, and invasion while HMGA2 knockdown has opposite effects, suggesting cooperation. Co-immunoprecipitation, ectopic overexpression, siRNA knockdown, cell proliferation/invasion assays Experimental and therapeutic medicine Low 36340602

Source papers

Stage 0 corpus · 38 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 Centromeric Aurora-B activation requires TD-60, microtubules, and substrate priming phosphorylation. Science (New York, N.Y.) 132 18218899
2022 The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability. Experimental & molecular medicine 113 35217832
2003 The mammalian passenger protein TD-60 is an RCC1 family member with an essential role in prometaphase to metaphase progression. Developmental cell 101 12919680
2013 MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2. Molecular cancer 83 23442884
2017 Overexpression of RCC2 Enhances Cell Motility and Promotes Tumor Metastasis in Lung Adenocarcinoma by Inducing Epithelial-Mesenchymal Transition. Clinical cancer research : an official journal of the American Association for Cancer Research 61 28606921
2018 LncRNA LCPAT1 Mediates Smoking/ Particulate Matter 2.5-Induced Cell Autophagy and Epithelial-Mesenchymal Transition in Lung Cancer Cells via RCC2. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 58 29913439
1998 Colocalization of TD-60 and INCENP throughout G2 and mitosis: evidence for their possible interaction in signalling cytokinesis. Chromosoma 47 9914378
2015 TD-60 links RalA GTPase function to the CPC in mitosis. Nature communications 41 26158537
2014 Coronin-1C and RCC2 guide mesenchymal migration by trafficking Rac1 and controlling GEF exposure. Journal of cell science 40 25074804
2018 RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation. BMC cancer 34 29321004
2021 BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression. Oncogene 30 34750516
2019 RCC2 promotes breast cancer progression through regulation of Wnt signaling and inducing EMT. Journal of Cancer 30 31839818
2018 MicroRNA-331-3p inhibits proliferation and metastasis of ovarian cancer by targeting RCC2. Archives of medical science : AMS 26 31749881
2019 RCC2 promotes proliferation and radio-resistance in glioblastoma via activating transcription of DNMT1. Biochemical and biophysical research communications 24 31277942
2025 High Sugar Induced RCC2 Lactylation Drives Breast Cancer Tumorigenicity Through Upregulating MAD2L1. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 23 40145796
2017 RCC2 is a novel p53 target in suppressing metastasis. Oncogene 23 28869598
2013 TD-60 is required for interphase cell cycle progression. Cell cycle (Georgetown, Tex.) 23 23388455
2022 The mitotic regulator RCC2 promotes glucose metabolism through BACH1-dependent transcriptional upregulation of hexokinase II in glioma. Cancer letters 22 36116740
2023 LncRNA HOTAIR enhances RCC2 to accelerate cervical cancer progression by sponging miR-331-3p. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20 36593385
2020 RCC2 Promotes Esophageal Cancer Growth by Regulating Activity and Expression of the Sox2 Transcription Factor. Molecular cancer research : MCR 19 32801160
2020 RCC2 contributes to tumor invasion and chemoresistance to cisplatin in hepatocellular carcinoma. Human cell 18 32239438
2019 RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 18 30768358
2012 Mass spectrometric analysis identifies a cortactin-RCC2/TD60 interaction in mitotic cells. Journal of proteomics 18 22282019
2023 RCC2 promotes prostate cancer cell proliferation and migration through Hh/GLI1 signaling pathway and cancer stem-like cells. Biology direct 15 38008751
2020 MicroRNA-191 modulates cisplatin-induced DNA damage response by targeting RCC2. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 10 32803782
2025 Inhibition of glutathione peroxidase 4 suppresses gastric cancer peritoneal metastasis via regulation of RCC2 homeostasis. Redox biology 9 39908861
2020 RCC2 Interacts with Small GTPase RalA and Regulates Cell Proliferation and Motility in Gastric Cancer. OncoTargets and therapy 9 32341655
2023 Long non-coding RNA (LncRNA) non-coding RNA activated by DNA damage (NORAD) knockdown alleviates airway remodeling in asthma via regulating miR-410-3p/RCC2 and inhibiting Wnt/β-catenin pathway. Heliyon 5 38261955
2020 RCC2 Expression Stimulates ER-Positive Breast Tumorigenesis. Journal of oncology 5 32565805
2025 RCC2 and CD24 cooperate to modulate prostate cancer progression through vimentin ubiquitination and β-catenin activation. The Journal of clinical investigation 4 41090358
2024 Promotive actions of lncRNA EBLN3P involved in cervical cancer progression via interacting with miR-29c-3p and TAF15 to modify RCC2. Archives of biochemistry and biophysics 3 38555043
2024 NudCL2 is required for cytokinesis by stabilizing RCC2 with Hsp90 at the midbody. Protein & cell 3 38801297
2024 circRNA-0015004 act as a ceRNA to promote RCC2 expression in hepatocellular carcinoma. Scientific reports 3 39043840
2022 A pan‑cancer analysis of RCC2 and its interaction with HMGA2 protein in an in vitro model of colorectal cancer cells. Experimental and therapeutic medicine 1 36340602
2026 Decoupling lactylation-associated metabolic remodelling in Asthma: Integrated multi-omics and machine learning identify RCC2 as a potential therapeutic target. Computer methods and programs in biomedicine 0 42000636
2025 Identification of RCC2 as a Risk Gene Associated With Basal Cell Carcinoma and Experimental Validation. Experimental dermatology 0 40129067
2025 Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes. JCO oncology advances 0 40330141
2023 Significance of RCC2, Rac1 and p53 Expression in Breast Infiltrating Ductal Carcinoma; An Immunohistochemical Study. Iranian journal of pathology 0 39118792

Missed literature

Know a paper Affinage missed for RCC2? Flag it for the maintainers and the community.

No submissions yet.